Hubei Jianxiang secures Russian GMP certificate for tirzepatide production

Hubei Jianxiang Biotechnology Pharmaceutical Co., Ltd., a controlling subsidiary of Sichuan Hexie Shuangma Co., Ltd., has obtained a Good Manufacturing Practice (GMP) certificate from the Russian Federation's Ministry of Industry and Trade. The inspection, conducted from July 30 to August 1, 2025, confirmed Hubei Jianxiang's compliance with EAEU GMP requirements for its production of tirzepatide active pharmaceutical ingredient.

The certificate, numbered GMP/EAEU/RU/02220-2025, was issued on September 4, 2025, and is valid from August 1, 2025, to July 31, 2028. This accreditation signifies official recognition of Hubei Jianxiang's quality management system, production, and quality control by Russian and Eurasian Economic Union authorities.

This achievement is expected to enhance Hubei Jianxiang's core competitiveness in the pharmaceutical sector, provide essential qualification for tirzepatide's market promotion in the region, and boost its influence in the international market. However, the announcement also cautions investors about potential market environment changes and exchange rate fluctuations affecting international sales.